JAZZ
Price
$126.13
Change
+$1.70 (+1.37%)
Updated
Aug 28 closing price
Capitalization
7.65B
68 days until earnings call
TECH
Price
$54.21
Change
-$0.12 (-0.22%)
Updated
Aug 29, 12:22 PM (EDT)
Capitalization
8.45B
67 days until earnings call
Interact to see
Advertisement

JAZZ vs TECH

Header iconJAZZ vs TECH Comparison
Open Charts JAZZ vs TECHBanner chart's image
Jazz Pharmaceuticals
Price$126.13
Change+$1.70 (+1.37%)
Volume$518.11K
Capitalization7.65B
Bio-Techne
Price$54.21
Change-$0.12 (-0.22%)
Volume$4.56K
Capitalization8.45B
JAZZ vs TECH Comparison Chart in %
Loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAZZ vs. TECH commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Buy and TECH is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (JAZZ: $126.13 vs. TECH: $54.33)
Brand notoriety: JAZZ and TECH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 70% vs. TECH: 185%
Market capitalization -- JAZZ: $7.65B vs. TECH: $8.45B
JAZZ [@Biotechnology] is valued at $7.65B. TECH’s [@Biotechnology] market capitalization is $8.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileTECH’s FA Score has 1 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, TECH is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 6 TA indicator(s) are bullish while TECH’s TA Score has 6 bullish TA indicator(s).

  • JAZZ’s TA Score: 6 bullish, 3 bearish.
  • TECH’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than TECH.

Price Growth

JAZZ (@Biotechnology) experienced а +4.65% price change this week, while TECH (@Biotechnology) price change was +0.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.14%. For the same industry, the average monthly price growth was +15.09%, and the average quarterly price growth was +29.14%.

Reported Earning Dates

JAZZ is expected to report earnings on Nov 05, 2025.

TECH is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (-1.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TECH($8.45B) has a higher market cap than JAZZ($7.65B). TECH has higher P/E ratio than JAZZ: TECH (118.11) vs JAZZ (15.38). JAZZ YTD gains are higher at: 2.420 vs. TECH (-24.246). JAZZ has higher annual earnings (EBITDA): 372M vs. TECH (283M). TECH has less debt than JAZZ: TECH (423M) vs JAZZ (5.43B). JAZZ has higher revenues than TECH: JAZZ (4.09B) vs TECH (1.21B).
JAZZTECHJAZZ / TECH
Capitalization7.65B8.45B91%
EBITDA372M283M131%
Gain YTD2.420-24.246-10%
P/E Ratio15.38118.1113%
Revenue4.09B1.21B338%
Total Cash1.67BN/A-
Total Debt5.43B423M1,284%
FUNDAMENTALS RATINGS
JAZZ vs TECH: Fundamental Ratings
JAZZ
TECH
OUTLOOK RATING
1..100
1552
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5259
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECH's Valuation (4) in the Biotechnology industry is significantly better than the same rating for JAZZ (77) in the Pharmaceuticals Other industry. This means that TECH’s stock grew significantly faster than JAZZ’s over the last 12 months.

JAZZ's Profit vs Risk Rating (85) in the Pharmaceuticals Other industry is in the same range as TECH (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

JAZZ's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as TECH (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

JAZZ's Price Growth Rating (52) in the Pharmaceuticals Other industry is in the same range as TECH (59) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

JAZZ's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as TECH (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to TECH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAZZTECH
RSI
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 3 days ago
58%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 4 days ago
60%
Bullish Trend 17 days ago
72%
Declines
ODDS (%)
Bearish Trend 19 days ago
56%
Bearish Trend 1 day ago
71%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
67%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TECH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEFRX30.940.07
+0.23%
First Eagle Rising Dividend Fund R6
AGREX9.25N/A
N/A
Invesco Global Real Estate A
GCIUX17.82N/A
N/A
Goldman Sachs Intl Eq Insghts R6
ETIDX19.84N/A
N/A
Eventide Dividend Growth I
FCTDX18.91N/A
N/A
Strategic Advisers Fidelity US TtlStk

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with AMLX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
+1.37%
AMLX - JAZZ
43%
Loosely correlated
-0.32%
TECH - JAZZ
43%
Loosely correlated
-3.36%
FTRE - JAZZ
40%
Loosely correlated
+6.87%
ROIV - JAZZ
39%
Loosely correlated
-0.42%
DAWN - JAZZ
38%
Loosely correlated
N/A
More